Omeros (OMER) closed at $18.27 on November 3, 2026, up 2.5% from the previous close, on volume of 871,812 shares (30-day average 1,180,762).
Data as of November 3, 2026.
3-Nov-2026
Globe Newswire (Tue, 3-Nov 5:41 PM ET)
Omeros Grants CEO New Performance-Based Stock Options
TipRanks (Fri, 30-Oct 5:39 PM ET)
Business Wire (Fri, 16-Oct 6:20 AM ET)
Surging YARTEMLEA Revenues and Bold Debt Reduction Mark Omeros’ Transformative Quarter
Market Chameleon (Thu, 13-Aug 6:32 AM ET)
Omeros Corporation Reports Second Quarter 2026 Financial Results
Business Wire (Wed, 12-Aug 4:02 PM ET)
Omeros Corporation to Announce Second Quarter Financial Results on August 12, 2026
Business Wire (Mon, 10-Aug 8:00 AM ET)
Market Chameleon (Fri, 26-Jun 4:36 AM ET)
Omeros Delivers First Profitable Quarter as YARTEMLEA Launch Transforms Financial Trajectory
Market Chameleon (Thu, 14-May 6:17 AM ET)
Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.
Omeros trades on the NASDAQ stock market under the symbol OMER.
As of November 3, 2026, OMER stock price climbed to $18.27 with 871,812 million shares trading.
OMER has a beta of 2.84, meaning it tends to be more sensitive to market movements. OMER has a correlation of 0.14 to the broad based SPY ETF.
OMER has a market cap of $1.32 billion. This is considered a Small Cap stock.
Last quarter Omeros reported $29 million in Revenue and $.02 earnings per share. This beat revenue expectation by $16 million and exceeded earnings estimates by $.34.
In the last 3 years, OMER traded as high as $21.24 and as low as $1.13.
The top ETF exchange traded funds that OMER belongs to (by Net Assets): VTI, IWM, VXF, BRNY, XPH.
OMER has outperformed the market in the last year with a price return of +154.8% while the SPY ETF gained +11.5%. OMER has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +45.5% and +10.4%, respectively, while the SPY returned -0.2% and -1.9%, respectively.
OMER support price is $17.13 and resistance is $18.53 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that OMER shares will trade within this expected range on the day.